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SUMMARY
The NOD mouse is an established model of autoimmune diabetes mellitus. Various lines of NOD
mice differ in their incidence of spontaneous diabetes, e.g. 93% of female NOD/Lt mice compared
with 46% of female NOD/Wehi mice develop diabetes by 250 days. These two lines were studied
under conditions which greatly accelerate the onset of hyperglycaemia. It was hoped that their
responses to these manipulations would reveal characteristic differences which would increase our
understanding of diabetes resistance in the low incidence NOD/Wehi line. One dose of 300 mg/kg of
cyclophosphamide (CP) produced hyperglycaemia in 50% ofNOD mice within 2 weeks in both lines.
They were also equally susceptible to diabetes induced by splenocyte transfer at 21 days of age from
prediabetic 150-day-old NOD/Lt or NOD/Wehi females. Five daily 40 mg/kg doses ofstreptozotocin
(STZ) resulted in a severity of diabetes in the NOD mice greater than in C57BL or SJL/J mice. While
the incidence and severity of diabetes induced in the two NOD lines were similar, this appeared to be
principally due to sensitivity to the toxic effects of STZ rather than its ability to exacerbate
autoimmune # cell destruction. It has previously been shown that it is possible to prevent diabetes in
susceptible NOD mice with simple, relatively benign therapies and here we show that it is possible to
induce diabetes in resistant animals at a rate indistinguishable from fully predisposed individuals. It
therefore appears that the prediabetic NOD mouse is poised in an immunologically precarious state
with the onset of disease being highly dependent on factors which exacerbate or moderate
autoimmune destruction.
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INTRODUCTION
NOD mice were derived from a single diabetic female JCL: ICR
outbred mouse which was found to be of low weight, polyuric,
polydipsic and glycosuric (Makino et al., 1980). Since their
description in 1980, many colonies have been established
throughout the world, and maintained in separate breeding
programmes. In addition to this potential genetic heterogeneity,
NOD mice are profoundly affected by environmental variables
such as diet (Elliott, et al., 1988; Scott, Daneman & Martin,
1988;Coleman, Kuzava & Leiter 1990) and exposure to patho-
gens (Oldstone, 1988; Leiter, 1990). As a result, the incidence of
diabetes in different lines varies greatly (Colony Information
Sheets, 1989). Two such lines are maintained in the same
environment at the Walter and Eliza Hall Institute (WEHI)
(Baxter, Adams & Mandel, 1989). This allows the direct
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cell transfer comparative immunology
comparison of immunological parameters mediating the rela-
tive resistance to diabetes in the lower incidence line.
The NOD/Lt line maintains a consistently high incidence of
diabetes in females at 250 days (93%), while the NOD/Wehi
females become diabetic less frequently (43%). Both lines
express a much lower incidence of disease in males (21 I/O versus
6%). Histological examination of islets reveals significantly
more severe mononuclear cell infiltration in the high incidence
(NOD/Lt) line. This supports our premise that the difference in
diabetes incidence results from differences in the severity of
autoimmune destruction occurring in the two lines (Baxter,
Koulmanda & Mandel, 1991).
To define further the immunological differences between the
NOD/Lt and NOD/Wehi lines, their responses to three mech-
anisms of accelerated autoimmune destruction were examined.
These mechanisms were: (i) the ablation of suppressor activity
with cyclophosphamide (CP); (ii) the passive transfer of auto-
reactive lymphocytes; and (iii) the increased exposure of
putative autoantigens by the repeated administration of subdia-
betogenic doses of the # cell toxin, streptozotocin (STZ).
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MATERIALS AND METHODS
Mice
NOD/Wehi mice were obtained from the colony derived from
breeding pairs provided by H. Asamoto (Kyoto, Japan) and
maintained at the WEHI since May 1984 (21 generations).
NOD/Lt mice were obtained from the colony derived from
breeding pairs obtained from Dr E. H. Leiter (Jackson Labora-
tory, Bar Harbour, MN) in January 1987 and maintained at the
WEHI for 10 generations. C57BL/KaWehi (F43), C57BL/
6JWehi (F58), and SJL/JWehi (F65) mice were obtained from
the animal breeding facilities of the WEHI. All mice were
allowed free access to food (Barastock mouse pellets, VIC.) and
acidified water.
Cyclophosphamide treatment
NOD mice 1 10 days old were bled for random serum glucose
estimation and weighed before i.p. injection of 300 mg/kg pure
crystalline CP (Pharmitalia, Italy) dissolved in 250 yl phos-
phate-buffered saline (PBS) or PBS alone. Mice were bled 14
days later, killed and their pancreata removed for histological
examination.
Splenocyte transfer
Spleens were harvested under sterile conditions from non-
diabetic 150-day-old female NOD mice. A single cell suspension
was prepared and red cells lysed in 0-168 M NH4CI at 370C. The
cells were then washed and resuspended in serum-free PBS.
Splenocytes (2-0 x I07 in 100 p1) were injected into the retro-
orbital plexus of 21-day-old weanlings under an operating
microscope. Control mice were either uninjected or injected with
2-0 x 107 y-irradiated (20 Gy) splenocytes. Recipients were
followed by 2 weekly random serum glucose estimations until
150 days of age.
Multiple low dose streptozotocin treatment
Mice 9 weeks of age were injected intraperitoneally with 40 mg/
kg STZ (Sigma, MO) dissolved in 250 p1 PBS daily for 5 days.
The treated mice were bled for serum glucose estimations at
5-day intervals for 30 days and then killed and their pancreata
removed for histological examination.
Serum glucose measurement
Each mouse was bled by retro-orbital vein puncture of 100-150
p1 and the serum glucose concentration measured by the glucose
oxidase technique with a Beckman Glucose Analyzer (Beck-
man, Fullerton, CA). A mouse was declared diabetic if it was
found to have a random serum glucose level > 12-0 mmol/l
followed by either rapid demise or further values > 12-0 mmol/l
on subsequent bleeds.
Histological assessment of insulitis
Pancreata were fixed in Bouins' fixative, transferred to alcohol,
paraffin embedded and sectioned at three levels. Slides were
stained with haematoxylin and eosin or Gomori aldehyde
fuchsin, and independently scored by two observers as pre-
viously described (Baxter et al., 1991). Briefly, a semi-objective
score from 0 to 4 was assigned to each islet. A score of 0
indicated an islet free of pathology, and a score of 4 indicated
virtually complete destruction. The scores were then totalled
and expressed as a percentage of the total possible score.
Table 1. The result of injecting I1 NOD/Lt and 15 NOD/Wehi non-
diabetic 110-day-old female mice with 300 mg/kg CP compared with
control PBS-injected mice. There was no significant difference between
the proportions of mice which died or became diabetic in the treated
groups (Fisher's exact test)
Line Treatment Dead Diabetic Non-diabetic Total
NOD/Lt Cyclo 1 5 5 11
NOD/Lt Saline 0 1 5 6
NOD/Wehi Cyclo 1 7 7 15
NOD/Wehi Saline 0 0 8 8
Statistical analysis
Comparison ofcumulative incidence ofdiabetes was made using
the x2 test. Yates' correction was applied if the expected
frequency of a cell was < 10-0 and the Fisher's exact probability
test was applied if the expected frequency of a cell was < 5-0. It
was assumed that weight and serum glucose maintained a
normal distribution, and Student's t-test was applied. In the case
of hyperglycaemia induced by STZ, the distribution of values
was clearly non-normal, and the rank sum test was applied. It
was assumed that the insulitis scores of pancreata maintained
the same distribution and the rank sum or Kruskal-Wallis tests
were applied.
RESULTS
Cyclophosphamide treatment
Twenty-three NOD/Wehi and 23 NOD/Lt 110-day-old female
mice were weighed and bled before CP treatment. Six NOD/Lt
mice were already diabetic and were excluded from analysis.
NOD/Wehi mice weighed an average of 23-3 g (s.d. 1-2 g) while
NOD/Lt mice weighted 25-3 + 1-0 g (P < 0-001, Student's t-test).
There was no significant difference between the pretreatment
serum glucose estimations. Fifteen NOD/Wehi and I I NOD/Lt
mice were injected with 300 mg/kg CP and the remaining mice
were injected with PBS. Two weeks after injection, one mouse
from each treatment group had died, and one-half of the
remaining mice in each treatment group were diabetic (Table 1).
To confirm the validity of this result a retrospective analysis
of CP-treated control groups from previous experiments com-
pleted within the laboratory over the previous 3 years was
carried out. Of 114 NOD/Wehi females aged 103-145 days 53%
became diabetic compared with 52% of 31 NOD/Lt female mice
aged 100-127 days when injected with 300-350 mg/kg CP (not
significant, x2 test).
Splenocyte transfer
Transfer of 2-0 x I07 splenocytes from 150-day-old non-diabetic
female NOD/Lt mice to 21-day-old female weanlings resulted in
an increase in the rate of diabetes onset in both lines (Fig. 1).
While NOD/Wehi mice initially appear to lag behind the NOD/
Lt line, this difference was not significant (1 1/21 (520/0) Lersus 3/
14 (21%) at 100 days; x2 test). Significantly more NOD/Lt
weanlings injected with NOD/Lt splenocytes became diabetic
by 150 days than either uninjected mice (P <0-01, X2 test) or
those injected with irradiated (20 Gy) splenocytes from 150-day-
old non-diabetic female NOD/Lt mice (P<0-001, X2 test with
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Fig. 1. Female weanlings 21 days old were injected with 2-0 x 10
splenocytes from 150-day-old non-diabetic female NOD/Lt mice. Mice
were bled 2-weekly and the onset of diabetes was defined as a serum
glucose estimation in excess of 12-0 mmol/l followed by either further
raised estimations or rapid demise.
Table 2. Weanlings were injected with splenocytes from 150-day-old
female NOD/Lt or NOD/Wehi mice, with irradiated splenocytes, or
uninjected. The incidence of diabetes in each group at 150 days was
compared using the x2 test or Fisher's exact probability test, as
appropriate
Group Donor Recipient Treatment Diabetic/total
A NOD/Lt NOD/Lt None 16/20 (80)*
B NOD/Wehi NOD/Lt None 10/13 (77)
C NOD/Lt NOD/Lt 20 Gy 2/13 (15)
D None NOD/Lt None 23/50 (46)
E NOD/Lt NOD/Wehi None 9/12 (75)
F NOD/Wehi NOD/Wehi None 6/8 (75)
G NOD/Lt NOD/Wehi 20 Gy 2/12 (17)
H None NOD/Wehi None 7/50 (14)
Statistical analysis: Groups A and B, Fisher's exact test (NS);
Groups A and C, X2 test (P < 0-001 ); Groups A and D, X2 test (P< 0-01);
Groups C and D, x2 with Yates' correction (NS); Groups E and F,
Fisher's exact test (NS); Groups E and G, x2 with Yates' correction
(P< 0-02); Groups E and H, Fisher's exact test (P < 0-0001); Groups G
and H, x2 test (NS); Groups A and E, x2 test (NS).
* Percentages in parentheses.
Yates' correction, Table 2). Significantly more NOD/Wehi
weanlings injected with NOD/Lt splenocytes became diabetic
by 150 days than either uninjected mice (P < 0-0001, Fisher's
exact probability test) or those injected with irradiated spleno-
cytes (P < 0-02, x2 test with Yates' correction, Table 2). There
was no significant difference between the proportion of injected
NOD/Wehi and NOD/Lt weanlings which became diabetic (X2
test, Table 2).
Curiously, the injection of irradiated splenocytes appeared
to lower the proportion of NOD/Lt diabetics. This effect was
,# not great enough to be of statistical significance (X2 with Yates'
correction).
Splenocytes harvested from 150-day-old non-diabetic
female NOD/Wehi mice were equally capable of inducing
I1 accelerated diabetes in this model, as there was no significant
difference between the proportions of either NOD/Lt or NOD/
Wehi weanlings which became diabetic by 150 days induced by
NOD/Wehi splenocytes and the proportions which became
diabetic after injection of NOD/Lt splenocytes (Fisher's test,
( Table 2). There was no significant difference in the intensity of
lymphocytic infiltrate in the pancreata of the experimental
groups (Kruskal-Wallis test).
Larger numbers of splenocytes injected did not further
accelerate disease onset as the injection of 2-0 x 107 NOD/Lt
splenocytes together with 2-0 x 107 NOD/Wehi splenocytes
resulted in the same proportion of diabetic mice as NOD/Lt
150 splenocytes alone (data not shown).
Low dose streptozotocin
Six NOD/Lt, six C57BL/KaWehi and six C57BL/6JWehi 9-
week-old male mice were injected daily for 5 days with STZ and
bled at 5-day intervals for 30 days. All mice except one C57BL/
KaWehi mouse became diabetic. The serum glucose was
significantly higher in Ohe NOD/Lt mice than either the SJL/
JWehi (P < 0-005) or the C57BL/KaWehi (P < 0-002, rank sum
test) mice. Lymphocytic infiltration and ,B cell destruction was
greatest in the NOD/Lt mice and least in the C57BL/KaWehi
mice (data not shown).
Six NOD/Lt, six C57BL/6JWehi and six SJL/JWehi 9-week-
old female mice were treated similarly. Three NOD/Lt and four
SJL/JWehi mice became mildly diabetic while no C57BL/
6JWehi mice did (not significant, Fisher's test). The serum
glucose levels of NOD/Lt (9-2-21-8, mean 14-2 mmol/l) and
SJL/JWehi (9-5-13 6, mean 13-1 mmol/l) mice were not signifi-
cantly different from each other but were from C57BL/6JWehi
(5-7-11-8, mean 9-7 mmol//) mice (P < 0-05, rank sum test).
Twenty-four NOD/Wehi and 23 NOD/Lt male 9-week-old
mice were weighed and bled before multiple low dose STZ
treatment. There was no significant difference between the
weights or pretreatment serum glucose estimations (Student's t-
test). All NOD/Wehi mice and 19 out of 23 NOD/Lt mice
became diabetic (P < 0-05, x2 test), but this is not likely to be of
real significance as the distribution ofserum glucose estimations
in both groups was similar and bimodal (Fig. 2). Eight of 24
NOD/Wehi and 9 out of 23 NOD/Lt mice fell into a 'low
responding' group with serum glucoses ranging from 9 4 to
25-0 mmol/l. The remainder were 'high responders', with the
majority having serum glucose estimations in excess of
40-0 mmol/l. There was no significant difference in the severity
of hyperglycaemia between the two lines (rank sum test).
DISCUSSION
In this paper we have shown that two lines ofNOD mice which
differ in their spontaneous incidence of diabetes respond
similarly to three different mechanisms of accelerated disease.
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Fig. 2. NOD/Lt and NOD/Wehi male mice were injected with five daily
doses of 40 mg/kg streptozotocin. Serum glucose estimations were
performed on the 30th day after the first injection. The severity of
hyperglycaemia is shown as a histogram demonstrating the proportion
of mice in each line with plasma glucose levels within each range.
Proportions are indicated as the probability a mouse will fall within each
given range. A bimodal response was seen in both lines.
Previous studies have addressed the issue of acceleration of
diabetes in NOD mice. Harada & Makino (1984) administered
two 150 mg/kg doses ofCP 2 weeks apart resulting in acute onset
of diabetes in the majority of NOD mice. This response was
maximal between the ages of 50 and 140 days. A single injection
of a higher dose (200-350 mg/kg) (Yasunami & Bach, 1988;
Charlton et al., 1989) was also effective, and the proportion of
animals rendered diabetic appeared to be dose-dependent
(Charlton et al., 1989). Splenocytes from animals rendered
diabetic in this manner were able to transfer disease to naive
recipients, indicating the mechanism of action was not # cell
toxicity (Yasunami & Bach, 1988). Animals injected with CP
could be 'rescued' from diabetes onset by multiple early
injections of spleen and lymph node cells, suggesting that the
acceleration of diabetes resulted from an imbalance in a
lymphoid compartment (Charlton et al., 1989). This imbalance
has been postulated to be a selective depletion of cells which
mediate immunological suppression, as CP has a similar action
in the induction of experimental allergic encephalomyelitis
(Lando, Teitelbaum & Arnon, 1980) and autoimmune diabetes
induced by multiple low dose STZ (Keisel et al., 1981).
Here we have shown the NOD/Wehi and NOD/Lt lines were
equally susceptible to CP-precipitated diabetes despite differing
in their incidence of spontaneous disease. If the action of CP in
this model is the selective depletion of suppression, this result
can be explained by supposing an increased level of suppression
in the NOD/Wehi line which normally reduces the incidence of
diabetes, but which is eradicated by CP treatment.
Acceleration of diabetes by splenocyte injection has been
studied in detail by several groups. Splenic T cells from NOD
mice respond to islet antigens in vitro by proliferation and the
production of IL-2. This response is first seen in 50-day-old
mice, and is maximal at 150 days (Nagata et al., 1989).
Splenocytes from overtly diabetic NOD mice can transfer
diabetes to irradiated adult (Wicker, Miller & Mullen, 1986) or
unirradiated neonatal (Bendelac et al., 1987) syngeneic mice.
This property is also found in the splenocytes of non-diabetic
NOD mice older than 50 days, and is maximal in female mice
older than 130 days (Bendelac et al., 1987), appearing to parallel
in vitro reactivity to islets. Disease transfer is dependent on
recipient and donor age and sex, and the number of cells
transferred.
It was hoped that this model would allow differentiation
between the activity of autoreactive T cells present in the
splenocyte inoculum and the resistance to transfer in the
recipient. The finding that both lines were equally susceptible to
induction of diabetes by NOD/Lt splenocytes suggested that
NOD/Wehi mice do not have a stronger 'suppressor' ofimmune
destruction than NOD/Lt mice, but rather that they simply
undergo a less vigorous autoimmune activation. However, this
hypothesis must also be discarded in view of the finding that
NOD/Wehi splenocytes were equally capable of transferring
disease. Thus, it is unlikely that the model suggested by Reich
et al. (1989a, 1989b) of two opposing populations of lympho-
cytes, one autoaggressive and the other regulatory, provides a
satisfactory explanation for the processes involved in this
model.
STZ is a broad spectrum antibiotic with diabetogenic
properties mediated by direct fi cell cytotoxicity (Rakieten,
Rakieten & Nadkarni, 1963). Five daily i.p. injections of a
subdiabetogenic dose (40 mg/kg) ofSTZ were found to result in
lymphocytic infiltration of the islets of Langerhans, autoim-
mune fi cell destruction and subsequent hyperglycaemia in
permissive strains (Like & Rossini, 1976). A regimen of six
35 mg/kg doses resulted in severe hyperglycaemia in males, but
only moderate hyperglycaemia in females despite inducing a
similar degree of lymphocytic infiltration. Furthermore, male
athymic mice were also susceptible to severe hyperglycaemia
despite the absence of an islet infiltrate (Leiter, 1982). Thus
diabetes induced by the multi-low dose STZ protocol appears to
involve the dual action of incremental toxic destruction and the
induction of autoimmunity to a fi cell neoantigen (reviewed in
Kolb, 1987). One possible source off, cell associated neoantigen
is C-type retrovirus-like particles which were noted to be
dramatically increased in the fl cells ofSTZ-treated mice (Like &
Rossini, 1976). Similar particles were seen in the cisternae of the
rough endoplasmic reticulum of prediabeticNOD mice (Fujino-
Kurihara et al., 1985) and were greatly increased following
treatment with CP (Suenaga & Yoon, 1988), suggesting a
common, retroviral, autoantigen in all three models.
Thus three possible mechanisms of JJ cell destruction
potentially occur in the low dose STZ model: incremental
toxicity, exposure and activation by novel STZ-induced anti-
gen(s), and increased exposure to an existing, stimulatory
autoantigen. The finding that it is unable to induce severe
hyperglycaemia in female NOD/Lt mice suggests that the third
mechanism does not play a role as there does not appear to be
any evidence of a primed response in mice that were undergoing
active autoimmune destruction of f, cells at the time of
treatment. The two NOD lines appeared to be equally suscep-
tible to both the toxic and autoimmune mechanisms.
It has previously been shown that it is possible to prevent
diabetes in susceptible NOD mice by manipulation of environ-
ment (Williams et al., 1990), diet (Elliott et al., 1988; Scott et al.,
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1988; Coleman et al., 1990) and exposure to pathogens (Old-
stone, 1988; Leiter, 1990). Here we show that it is possible to
induce diabetes in relatively resistant animals at a rate indis-
tinguishable from fully predisposed individuals. These experi-
ments throw little light on the mechanism of resistance to
diabetes in the NOD/Wehi mice. While the CP data are
consistent with an increased level of suppressor activity, the cell
transfer experiments do not support this hypothesis. Paradoxi-
cally, the cell transfer experiments are not consistent with a less
aggressive autoimmune attack either. The STZ experiments fail
to resolve this problem, as the mechanism of action appears not
to be related to the pre-existing autoimmune destruction
occurring in the NOD. It is clear, however, that regardless of the
mechanism of resistance in the NOD/Wehi line, it is easily
overcome by experimental manipulation. It therefore appears
that the prediabetic NOD mouse is poised in an immunologi-
cally precarious state with the onset of disease being highly
dependent on factors which exacerbate or moderate autoim-
mune destruction.
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